Our top pick for
Building a portfolio
The Joint Corp is a medical care facilities business based in the US. The Joint shares (JYNT) are listed on the NASDAQ and all prices are listed in US Dollars. The Joint employs 150 staff and has a trailing 12-month revenue of around USD$55.5 million.
|Latest market close||USD$26.26|
|52-week range||USD$7.67 - USD$27.91|
|50-day moving average||USD$25.8815|
|200-day moving average||USD$18.9383|
|Wall St. target price||USD$27.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.26|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-13)||-8.21%|
|1 month (2020-12-23)||1.19%|
|3 months (2020-10-20)||41.72%|
|6 months (2020-07-20)||74.37%|
|1 year (2020-01-19)||N/A|
|2 years (2019-01-19)||N/A|
|3 years (2018-01-19)||433.25%|
|5 years (2016-01-20)||542.05%|
Valuing The Joint stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of The Joint's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
The Joint's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 98x. In other words, The Joint shares trade at around 98x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
The Joint's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$6.7 million.
The EBITDA is a measure of a The Joint's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$55.5 million|
|Operating margin TTM||7.21%|
|Gross profit TTM||USD$42.9 million|
|Return on assets TTM||5.34%|
|Return on equity TTM||57.87%|
|Market capitalisation||USD$358.6 million|
TTM: trailing 12 months
There are currently 1.1 million The Joint shares held short by investors – that's known as The Joint's "short interest". This figure is 4.2% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting The Joint shares can be evaluated.
The Joint's "short interest ratio" (SIR) is the quantity of The Joint shares currently shorted divided by the average quantity of The Joint shares traded daily (recently around 84492.518518519). The Joint's SIR currently stands at 13.5. In other words for every 100,000 The Joint shares traded daily on the market, roughly 13500 shares are currently held short.
However The Joint's short interest can also be evaluated against the total number of The Joint shares, or, against the total number of tradable The Joint shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case The Joint's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 The Joint shares in existence, roughly 80 shares are currently held short) or 0.0987% of the tradable shares (for every 100,000 tradable The Joint shares, roughly 99 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against The Joint.
Find out more about how you can short The Joint stock.
We're not expecting The Joint to pay a dividend over the next 12 months.
Over the last 12 months, The Joint's shares have ranged in value from as little as $7.67 up to $27.91. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while The Joint's is 1.2609. This would suggest that The Joint's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising and the sale of regional developer rights. As of December 31, 2019, the company operated approximately 513 clinics in the United States. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.